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Hand, Foot and Mouth DiseaseEnterovirus 71 (EV71) is one of the main etiological agents for Hand, Foot and Mouth Disease
(HFMD) and has been shown to be associated with severe clinical manifestation. Currently, there
is no antiviral therapeutic for the treatment of HFMD patients owing to a lack of understanding
of EV71 pathogenesis. This study seeks to elucidate the transcriptomic changes that result from
EV71 infection. Human whole genome microarray was employed to monitor changes in genomic
proﬁles between infected and uninfected cells. The results reveal altered expression of human genes
involved in critical pathways including the immune response and the stress response. Together, data
from this study provide valuable insights into the host–pathogen interaction between human colo-
rectal cells and EV71.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Enterovirus 71 (EV71) is a positive sense, single stranded, non-
enveloped RNA virus belonging to Enterovirus genus of the Picor-
naviridae family [1–4]. It is one of the main etiological agents for
Hand, Foot and Mouth Disease (HFMD) which commonly affects
infants and children. This disease is usually self-limiting, charac-
terised by various symptoms such as fever, rashes, poor appetite
and multiple ulcers in mouth [5–7]. The route of transmission of
EV71 was postulated to happen via direct contact of vesicular ﬂuid
or droplet from the infected or via faecal-oral route [5,8–10]. EV71
was shown to replicate within the gastrointestinal tract, bypass thegut barrier and infect into the skeletal muscle cell before entering
into the bloodstream and the central nervous system [5,8–10].
However, unlike other HFMD causing enteroviruses, EV71 have
been commonly associated with severe clinical diseases, including
neurological diseases leading to cardiopulmonary failure and
death.
EV71 was ﬁrst described in 1974 in CA (USA) after it was iso-
lated from patients with central nervous system disease in 1969
[11]. Recent molecular evolution studies have predicted that
EV71 could have emerged in the human population as early as
1941 [12–14]. Large fatal outbreaks of HFMD ﬁrst appeared in Bul-
garia in 1975, and disease outbreaks were subsequently identiﬁed
in Hungary in 1978 and re-emerged after two decades in Malaysia
in 1997 and Taiwan in 1998 [15–19]. Since then, there have been
various outbreaks, epidemics and pandemics that have periodically
been reported worldwide with outbreaks occurring every two to
three years in countries including Australia, China, Taiwan, Japan,
Korea, Malaysia, Vietnam, Thailand and Singapore [7,11,15,20].
Currently and due in part to a lack of understanding of viral
pathogenesis of EV71 causing HFMD, there are no effective antivi-
ral therapies or vaccines approved by the United States Food and
Table 1
Primers used in this study.
Primers 50–30
EV71-VP1-reverse GCTCTATAGGAGATAGTGTGAGTAGGG
EV71-VP1-forward ATGACTGCTCACCTGCGTGTT
IL29/IFN lambda1-forward ACCGTGGTGCTGGTGACTT
IL29/IFN lambda1-reverse CTAGCTCCTGTGGTGACAGA
IFN beta1-forward ATGACCAACAAGTGTCTCCTCC
IFN beta1-reverse GGAATCCAAGCAAGTTGTAGCTC
IFN gamma1-forward TCTTTGGGTCAGAGTTAAAGCCA
IFN gamma1-reverse TTCCATCTCGGCATACAGCAA
ISG54-forward AAGCACCTCAAAGGGCAAAAC
ISG54-reverse TCGGCCCATGTGATAGTAGAC
ISG56-forward TTGATGACGATGAAATGCCTGA
ISG56-reverse CAGGTCACCAGACTCCTCAC
b-Actin forward ACCAACTGGGACGACATGGAGAAA
b-Actin reverse TAGCACAGCCTGGATAGCAACGTA
Y.L.E. Lui et al. / FEBS Open Bio 4 (2014) 426–431 427Drug Administration (FDA) to prevent HFMD. There is therefore a
need to gain a better understanding of the mechanism of EV71
pathogenesis. The ability to cause infection directly correlates to
the interaction between the host and pathogen. In order to survive
and proliferate during infection, the pathogen must be able to
sense, react and adapt to the ever-changing microenvironment
within the host. Such adaptations and the use of the host resources
to proliferate are prerequisites for the successful colonisation of
the host and establish disease. Viruses, being obligate intracellular
parasites have developed highly sophisticated mechanisms not
only to exploit the biosynthetic machinery for replication, but also
to speciﬁcally evade the host immune system.
During infection, viruses regulate host gene expression to
enhance their survival. Such activities include altering the cellular
microenvironment to allow successful virus replication and evasion
of the host immune system [21–23]. Elucidating the mechanism
that the virus uses to bypass host defence systems and establish
infections will provide us with a better understanding of the path-
ogenesis mechanism of the EV71 virus and will thus aid in the
development of potential antiviral therapeutics for HFMD patients.
In this study, transcriptomics proﬁling was performed using colo-
rectal cells infected with EV71 using mRNA microarray.
2. Materials and methods
2.1. Cell culture and virus propagation
Human colorectal cell line (HT29) (ATCC Catalog No. HTB-
38™) was maintained in Roswell Park Memorial Institute medium
(RPMI) (PAA Laboratories, Austria) supplemented with 10% (v/v)
Fetal Bovine Serum (FBS) (PAA Laboratories, Austria) and 2%
penicillin–streptomycin (PAA Laboratories, Austria) at 37 C with
5% CO2. The EV71 strain used in this study was isolated from a fatal
case of HFMD during October 2000 outbreak in Singapore, Entero-
virus 5865/sin/000009 strain from subgenogroup B4 (accession
number 316321; hereby designated as Strain 41). The virus stock
was prepared by propagation of viruses using 90% conﬂuent
HT29 cells monolayer in RPMI with 10% FBS at 37 C with 5%
CO2. The virus titres were determined using 50% tissue culture
infective dose (TCID50) per millilitre (mL) according to Reed and
Muench method [24].
2.2. EV71 infection for mRNA proﬁling
HT29 cells were seeded at a concentration of 5  105 cells/mL in
each well of a 6-well plate and incubated for 24 h at 37 C with 5%
CO2. Cells were washed twice with phosphate buffered saline (PBS)
and infected with EV71 at multiplicity of infection (MOI) of 1 or nil
respectively. The culture media were removed and replaced with
2 mL of fresh RPMI medium after 1 h of incubation at 37 C with
5% CO2. The respective infected cells were harvested at 36 h posts
infection (hpi). The total cellular RNA of HT29 cells were extracted
using the miRNeasy mini kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. Brieﬂy, the cells were lysed and
homogenise using lyses solution provided (Qiagen, Hilden, Ger-
many). Total RNA were puriﬁed using the RNeasy spin column
and eluted (Qiagen, Hilden, Germany). Harvested total RNA was
quantitated using Nanodrop 100 spectrophotometer (ThermoSci-
entiﬁc, Waltham, USA).
2.3. mRNA microarray analysis
Extracted total RNA were labelled with GeneChip HT 30 IVT
Express Kit following manufacturer’s instruction. Hybridization
to GeneChip PrimeView Human Gene Expression Array was
performed in accordance to manufacturer’s recommendations.Every chip was scanned at a high resolution by the Affymetrix
GeneChip Scanner 3000 according to the GeneChip Expression
Analysis Technical Manual procedures (Affymetrix, Santa Clara,
CA). Brieﬂy, total extracted RNA undergo two rounds of cDNA syn-
thesis prior to in vitro transcription to synthesise biotin modiﬁed
ampliﬁed RNA (Affymetrix, Santa Clara, CA). The ampliﬁed RNA
was puriﬁed and fragment for the hybridisation onto the GeneChip
PrimeView Human Gene Expression Array (Affymetrix, Santa Clara,
CA). Raw data for the microarray were analysed with the Partek
Genomics Suite (Partek Incorporated, Saint Louis, USA) where
p < 0.05 is considered signiﬁcant.
2.4. cDNA synthesis and quantitative real time polymerase chain
reaction
For the conversion of mRNA to cDNA, 1 lg of the total RNA was
reverse transcripted using using the iScript™ cDNA Synthesis Kit
(Bio-Rad Laboratories, CA, USA) in accordance to the manufac-
turer’s instructions. Brieﬂy, 1 lg of the extracted RNA was mixed
with enzyme reverse transcriptase and buffer to a volume of
20 ll and subjected to thermal proﬁle of 25 C for 5 min, 42 C
for 30 min followed by 85 C for 5 min in accordance to the manu-
facturer’s instructions.
The quantitative real time polymerase chain reaction (qPCR)
was performed using the iTaq™ Universal SYBR Green Supermix
(Bio-Rad Laboratories, CA, USA) on the BioRad CFX96™ Real-Time
PCR system (Bio-Rad Laboratories, CA, USA). The primers used in
this study are listed in Table 1. Brieﬂy, 1 ll of cDNA and 1 ll of
the forward and the reverse primers were added to iTaq™ Univer-
sal SYBR Green Supermix. The reaction mix was then subjected to
thermal proﬁle of denaturation at 95 C for 30 s, followed by ampli-
ﬁcation and quantiﬁcation in 40 cycles at 95 C for 5 s followed by
60 C for 30 s. At the end of ampliﬁcation cycles, melting tempera-
ture analysis was performed by the BioRad CFX96TM Real-Time
PCR system (Bio-Rad Laboratories, CA, USA). Relative gene expres-
sion was quantiﬁed based on 2DDCT method using the housekeep-
ing gene b-actin as the reference gene [25].
2.5. Data analysis
All statistical analysis was performed on GraphPad Prism Ver-
sion 6.0c (GraphPad Software, USA). Student’s t test was used to
compare two groups. p values of <0.05 were considered statisti-
cally signiﬁcant.
3. Result and discussion
Systemic analyses of host response to EV71 provide critical clues
to understand the molecular mechanism of EV71 pathogenesis
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host cellular system can also bemonitored by studying the host cel-
lular transcriptomics change following enterovirus infection. Trans-
criptomics analysis via RNA-sequencing, mRNAmicroarray and PCR
array have been previously used to analyse host gene expression
[26–28]. However, these studies have been performed on rhabdo-
myosarcoma (RD) cells or SH-SY5Y cells, of muscle cells or neuronal
origin respectively. In a clinical context, this may not be a goodFig. 1. Heat map of the microarray mRNA expression proﬁle of EV71 infected and non-
showed differential expressed mRNAs of two groups of samples. The mRNAs were chos
expression and red represent mRNAs with increased expression. (n = 3, ⁄p values of <0.0
Fig. 2. Pathway analysis of differentially expressed genes of EV71 infected and non-in
generated using Partek Genomics Suite (Partek Incorporated, Saint Louis, USA) (n = 3).representative model during EV71 infection of a human host as
various studies have demonstrated that the gastrointestinal tract
was the ﬁrst site for EV71 proliferation [29–31]. Considering that
different cell types have varying cellular content, host–pathogen
interaction may differ from cell types to cell types [1,32,33]. We
have previously reported a human colorectal adenocarcinoma cell
line (HT29) with epithelioid morphology as a useful in vitro model
to study the pathogenesis of EV71 [33]. To this end, this studyinfected control colorectal cells, HT29. The two-way hierarchical cluster heat map
en according to the cut off p < 0.05 where blue represents mRNAs with decreased
5).
fected control colorectal cells, HT29. Pathways with enrichment score of <2 was
Y.L.E. Lui et al. / FEBS Open Bio 4 (2014) 426–431 429utilised HT29 as a model for the transcriptomics analysis of host
response to EV71 infection.
3.1. Identiﬁcation of deregulated mRNAs during EV71 infection
To identify the differentially transcribed mRNAs in HT29 during
EV71 infection, we perform mRNAs proﬁling using GeneChip
PrimeView Human Gene Expression Array. Comparative mRNAs
expression between EV71 infected cells and control non-infected
cells were performed. Microarray hybridisation identiﬁed 699
genes being differentially expressed signiﬁcantly during EV71Fig. 3. Expression level of types I, II and III IFN signalling pathways in response to
EV71 infection. Conﬂuent HT29 cells were infected with or without EV71 (MOI of 1).
Total intracellular RNA were harvested 36 hpi, converted to cDNA and measured by
quantitative real time polymerase chain reaction (qPCR). (A) Expression of IL29/IFN-
k1; (B) expression of IFN-b1; (C) expression of IFN-c1 (n = 3, ⁄p values of <0.05).infection (p < 0.05) (Fig. 1 and Supplementary Table 1). Using
Partek Genomics Suite, 699 differentially transcribed genes
between EV71 infected and control non-infected HT29were further
analyses to generate pathways with enrichment score of <2 (Fig. 2).
These differentially transcribed genes were involved in critical
pathways including the immune response, the stress response,
metabolism, cytotoxicity, cytokines and the cytoskeleton network
(Fig. 2).
In response to viral infection, cells were known to induce an
immunological response to combat against invading pathogens.
In particular, immune response cytokines IL29/interferon (IFN)-
k1 and IFN-b1 were signiﬁcantly up-regulated in EV71 infected
cells (Supplementary Table 1). The microarray results were vali-
dated using qPCR. In line with the microarray ﬁndings, qPCR
revealed that both IL29 and IFN-b1 were signiﬁcantly up-regulated
by approximately 20 fold and 3 fold in EV71 infected cells respec-
tively (Fig. 3a and b). This is not surprising as that both IL29 and
IFN-b1 are cytokines which play important roles in host antiviral
response [34–36]. In addition, IL29 has been previously reported
to be up regulated during viral infection such as inﬂuenza A, hep-
atitis C virus and Sendai viruses [34–36]. A key characteristic of
cytokines is the ability to interact with one another to establish
coordinated defence mechanism against invading pathogens. IL29
functions by binding to a unique receptor through a pathway iden-
tical to IFN-b1 and IFN-c1 receptors inducing cellular antiviral
activity to inhibit virus replication [34–36]. Synergetic effect
between IL29, IFN-b1 and IFN-c1 were shown to promote cellularFig. 4. Expression level of interferon stimulated genes in response to EV71
infection. Conﬂuent HT29 cells were infected with or without EV71 (MOI of 1).
Total intracellular RNA were harvested 36 hpi, converted to cDNA and measured by
quantitative real time polymerase chain reaction (qPCR). (A) Expression of ISG54;
(B) expression of ISG56 (n = 3, ⁄p values of <0.05).
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IFN-c1 as antiviral treatment has been shown to inhibit various
viruses including herpes simplex-1 virus, mouse hepatitis virus
type 2, human T-lymphotropic virus-1, cytomegalovirus and hepa-
titis C virus [37–43]. As such during EV71 infection, HT29 may up
regulate cytokines such as IL29, IFN-b1 and IFN-c1 (types I, II and
III IFN) to induce interferon stimulated genes (ISG) as part of
cellular antiviral response to slow down virus replication.
To further verify this reasoning, we performed qPCR on IFN-
gamma1 receptor, ISG54 and ISG56 to investigate if these genes
have been up regulated during EV71 infection. In agreement with
our hypothesis, our qPCR results show signiﬁcant up regulation
of these cytokines in response to EV71 infection (Figs. 3c and 4a,
b). This support notion that the host colorectal cells up-regulate
cytokines such as IL29, IFN-b1 and IFN-c1 (types I, II and III IFN)Fig. 5. Schematic illustration of the interplay between types I, II and III IFN
pathways and invading viral pathogen-EV71. Following EV71 infection, host
activate types I, II and III IFN pathways through a series of JAK-STAT signalling
cascade to mobilise interferon stimulated genes such as ISG54 and ISG56 in attempt
to slow down virus replication.possibly by a series of JAK-STAT signalling pathways to induce
ISG such as ISG54 and ISG56 (Fig. 5). However, Lei et al. (2010,
2011, 2013) previously reported that EV71 3C protein suppressed
the host immune system, for example type I interferon, during
infection in RD cells (muscle cells) [44–46]. As such, the mecha-
nism whereby EV71 mediate host immune system may differ from
cell type to cell types. To support this hypothesis, Chi et al. (2013)
have compared the expression of IFN-signalling pathway between
intestinal epithelial cells and muscle cells, which demonstrates
that intestinal cells have indeed a signiﬁcant higher expression of
cytokines response in comparison with muscle cells [47]. This
may explain the fact it takes three times longer for the virus to kill
HT29 cells in comparison with RD cells [32,33]. In addition, IFN sig-
nalling pathways such as type I interferon was previously demon-
strated to play an important role during EV71 pathogenesis [48].
Effectively, the intestinal epithelial immune system, being the
initial site of infection, plays a critical role in the disease progres-
sion and clinical prognosis. Impaired or immature immunity has
previously been associated with increased morbidity and mortality
in EV71 of young children and immune deﬁcient adults [48].The
ability to eliminate viral pathogen such as EV71 at the initial site
of infection is critical as a weaker immune response results in a
higher viral titre leading to a systemic spread with more serve
complications [47]. One of the key antiviral responses that the
intestinal epithelial immune system utilises may be the types I, II
and III IFN to eliminate invading EV71 (Fig. 5).
4. Conclusion
In conclusion, this study utilised HT29 as an in vitro model to
investigate on the transcriptomic changes in human colorectal
cells in response to EV71 infection. Human whole genome micro-
array was employed to monitor changes in proﬁles between
EV71 infected cells and uninfected control cells. The result reveals
altered expression of human mRNAs in selected pathways includ-
ing the immune response, the stress response, metabolism, cyto-
toxicity, cytokines and the cytoskeleton network. Interestingly,
our results shows signiﬁcant up regulation of types I, II and III
IFN which suggests that during EV71 infection, this may be the
key antiviral response HT29 cells undertake to eliminate invading
EV71. Taken together, data from this study provide valuable funda-
mental information toward understanding of host–pathogen inter-
action between human colorectal cells and invading EV71.
Elucidating the mechanism that the virus uses to bypass host
defence systems and establish infections will provide us with a
better understanding of the pathogenesis mechanism of the EV71
virus and will thus aid in the development of potential antiviral
therapeutics for HFMD patients.
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